Skip to content

Arvinas ARVN Free cash flow

Free cash flow at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$72.96M-13.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$89.27M-12.1%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$39.24M+16.7%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$38.03M-5.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$138M-3.8%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's free cash flow?
Arvinas (ARVN) reported free cash flow of -$70.5M in Q1 2026.
How has Arvinas's free cash flow changed year-over-year?
Arvinas's free cash flow increased by 21.1% year-over-year, from -$89.3M to -$70.5M.
What is the long-term trend for Arvinas's free cash flow?
Over 3 years (2021 to 2025), Arvinas's free cash flow has grown at a -22.5% compound annual growth rate (CAGR), from $592.3M to -$275.7M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.